Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall Street - shutterstock_1321462400
Stocks Set to Open Higher as Investors Await U.S. Jobs Data and Big Tech Earnings, Fed Meeting on Tap Barchart - Mon Jul 29, 4:39AM CDT

September S&P 500 E-Mini futures (ESU24) are up +0.29%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.38% this morning as market participants looked ahead to earnings reports from major tech...

ESU24 : 5,646.00 (+0.12%)
NQU24 : 19,470.75 (+0.16%)
MMM : 132.87 (-0.52%)
CHTR : 339.44 (+0.03%)
DECK : 157.32 (+1.43%)
DXCM : 69.10 (+0.23%)
MSFT : 431.30 (-0.88%)
AMZN : 186.14 (-0.40%)
META : 537.72 (+0.26%)
AAPL : 220.06 (+1.51%)
SBUX : 95.96 (-0.50%)
MCD : 291.53 (-0.76%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase FinancialNewsMedia - Mon Jun 17, 8:45AM CDT

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 1.8000 (-1.10%)
BPTH : 1.0200 (-2.67%)
LGVN : 2.05 (+1.99%)
SLS : 1.2400 (-1.59%)
BMY : 49.64 (+0.30%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase GlobeNewswire - Mon Jun 17, 8:45AM CDT

ATNM : 1.8000 (-1.10%)
BPTH : 1.0200 (-2.67%)
LGVN : 2.05 (+1.99%)
SLS : 1.2400 (-1.59%)
BMY : 49.64 (+0.30%)
Longeveron (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call Investor Brand Network - Fri May 3, 9:01AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.05 (+1.99%)
Longeveron (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase Investor Brand Network - Mon Apr 29, 9:28AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2,...

LGVN : 2.05 (+1.99%)
Longeveron (NASDAQ: LGVN) Closes on Warrant Exercise Offering, Public Offering Investor Brand Network - Mon Apr 22, 10:22AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.05 (+1.99%)
Longeveron (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M Investor Brand Network - Thu Apr 18, 9:30AM CDT

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.05 (+1.99%)
Longeveron (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M Investor Brand Network - Mon Apr 15, 9:01AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.05 (+1.99%)
Longeveron (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering Investor Brand Network - Wed Apr 10, 8:37AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 2.05 (+1.99%)
Longeveron (NASDAQ: LGVN) Discusses 2023 Progress, 2024 Plans in Corporate Update Investor Brand Network - Mon Apr 1, 9:36AM CDT

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for...

LGVN : 2.05 (+1.99%)

Barchart Exclusives

Dividend Aristocrats: The Best of the Best for Stable Income Barchart - 27 minutes ago
Dividend Aristocrats' ability to increase their dividends indicates strong earnings and a solid business foundation, which lowers investment risk. Moreover, their consistent earnings growth often enables them to outperform broader market indices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot